Immunome Inc. (IMNM): Price and Financial Metrics

Immunome Inc. (IMNM): $3.42

0.17 (+5.23%)

POWR Rating

Component Grades













Add IMNM to Watchlist
Sign Up

Industry: Biotech



in industry

IMNM Stock Price Chart Interactive Chart >

Price chart for IMNM

IMNM Price/Volume Stats

Current price $3.42 52-week high $27.80
Prev. close $3.25 52-week low $2.09
Day low $3.12 Volume 26,900
Day high $3.49 Avg. volume 72,836
50-day MA $4.14 Dividend yield N/A
200-day MA $11.96 Market Cap 41.47M

Immunome Inc. (IMNM) Company Bio

Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

IMNM Latest News Stream

Event/Time News Detail
Loading, please wait...

IMNM Latest Social Stream

Loading social stream, please wait...

View Full IMNM Social Stream

Latest IMNM News From Around the Web

Below are the latest news stories about Immunome Inc that investors may wish to consider to help them evaluate IMNM as an investment opportunity.

Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron Virus

Immunome Inc (NASDAQ: IMNM ) shares rose before falling after reporting results from testing its experimental three-antibody cocktail against live versions of the COVID-19 omicron variant . CEO Purnanand Sarma said that there had been a significant reduction in the number of antibody therapeutics under emergency use authorization that are active against omicron in recent weeks. That trend, he said, demonstrates … Full story available on

Benzinga | February 8, 2022

Immunome rises 9% as antibody cocktail shows efficacy against Omicron in in-vitro test

Immunome (IMNM) said in vitro data showed effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two

Seeking Alpha | February 8, 2022

Immunome shares seesaw after reporting antibody 'cocktail' passes test against live omicron virus

During the past two years, Immunonome has received more than $17.5 million from the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to support the company's development of the new drug candidate.

Yahoo | February 8, 2022

Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing

EXTON, Pa., February 08, 2022--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced in vitro data demonstrating effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two external laboratories (Boston University’s National Emerging Infectious Diseases Laboratories and Washington University1).

Yahoo | February 8, 2022

The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo Combo In Solid…

Business Insider Markets | January 11, 2022

Read More 'IMNM' Stories Here

IMNM Price Returns

1-mo -3.66%
3-mo -48.02%
6-mo -79.85%
1-year -85.19%
3-year N/A
5-year N/A
YTD -73.61%
2021 33.88%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8232 seconds.